Aytu Biopharma, INC

Aytu BioPharma and Lannett Company have mutually agreed to terminate their exclusive license agreement for Metadate CD effective June 23, 2026.

Aytu BioPharma announced its fiscal 2026 third quarter results, reporting $12.4 million in net revenue, a decrease from the prior year, with new drug EXXUA contributing $2.4 million.

Aytu BioPharma has amended outstanding warrants to clarify beneficial ownership blockers, aiming to reclassify warrant liabilities as equity.

Aytu BioPharma reports fiscal Q2 2026 results with decreased net revenue and a significant net loss, alongside the commercial launch of its new MDD treatment, EXXUA.

Aytu BioPharma recapped its Investor Day, focusing on the commercial launch and market opportunity for EXXUA, its novel antidepressant for Major Depressive Disorder.

Aytu BioPharma, Inc. announced the results of its 2026 annual meeting, where stockholders re-elected all incumbent directors, ratified Grant Thornton LLP as its independent auditor, and approved executive compensation.

Aytu BioPharma reported a 33% revenue decline in Q3 2026, primarily due to a strategic shift from ADHD products to EXXUA, with the new drug's launch partially offsetting the decrease.

Aytu BioPharma reported a significant net loss for the second fiscal quarter and first half of 2026, driven by derivative warrant liabilities and a strategic pivot towards its newly launched antidepressant, EXXUA, while divesting non-core assets.

Aytu BioPharma reports a net income of $1.965 million for Q1 fiscal 2026, driven by a derivative warrant liabilities gain, as it prepares for the anticipated launch of its major depressive disorder treatment, EXXUA.

Aytu BioPharma reports a profitable third quarter in fiscal year 2025, driven by revenue growth in its ADHD and Pediatric portfolios and effective cost management.

Aytu BioPharma's Q2 2025 results reveal a revenue decrease due to payer changes and competitor activity, alongside strategic efforts to streamline operations and manage costs.

Aytu BioPharma's Q1 2025 results show a net income of $1.474 million, driven by the ADHD portfolio and a strategic divestiture, despite a slight decrease in overall revenue.

Aytu BioPharma licenses EXXUA for MDD and raises $16.6M to support commercialization.

Aytu BioPharma reports a net loss of $15.8 million for fiscal year 2024, while strategically shifting focus to its Rx segment and completing the divestiture of its Consumer Health segment.

Joshua R. Disbrow, Chief Executive Officer and a Director of Aytu Biopharma, Inc, received 30,000 shares of common stock on July 28, 2026.

Greg Pyszczymuka, Chief Commercial Officer of Aytu Biopharma, Inc, received 20,000 shares of common stock on July 28, 2026.

Jarrett Disbrow, Chief Business Officer of Aytu Biopharma, Inc, received 15,000 shares of common stock on July 28, 2026.

Ryan J Selhorn, Chief Financial Officer of Aytu Biopharma, Inc, received 25,000 shares of common stock on July 28, 2026.

Vivian H Liu, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

Abhinav Jain, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

AYTU Biopharma, Inc. has filed definitive additional proxy soliciting materials with the U.S. Securities and Exchange Commission.

Aytu BioPharma, Inc. announces its 2026 annual meeting of stockholders to be held on December 10, 2025, detailing proposals for director elections, auditor ratification, and executive compensation.

Aytu BioPharma has filed a definitive proxy statement with the SEC.

Aytu BioPharma is holding its annual meeting on May 21, 2025, seeking stockholder approval for several proposals, including an amendment to the 2023 Equity Incentive Plan to increase the number of shares reserved for issuance.

Aytu BioPharma, Inc. has filed a definitive proxy statement with the SEC.

Aytu BioPharma will hold its annual meeting of stockholders on June 26, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.

Aytu BioPharma, Inc. has filed a Rule 462(b) registration statement to increase the maximum aggregate offering price of its ongoing public offering by an additional $2.76 million, bringing the total potential offering to $16.56 million.

Aytu BioPharma, Inc. filed an Amendment No. 1 to its S-1 Registration Statement, primarily to update the filing fee table for a proposed offering of common stock and prefunded warrants, and to delay the effective date.

Aytu BioPharma, Inc. has filed an S-1 registration statement for a public offering of common stock and prefunded warrants, detailing its strategic pivot to focus on prescription therapeutics, including a new exclusive commercialization agreement for a Major Depressive Disorder treatment, alongside mixed financial results and ongoing patent litigation.

Nantahala Capital Management, LLC and its principals have increased their beneficial ownership in Aytu BioPharma, Inc. to 14.4% by acquiring prefunded warrants for 4 million shares in a recent underwritten offering.

Laurence W. Lytton and Lytton-Kambara Foundation updated their passive beneficial ownership in AYTU Biopharma, Inc., reporting stakes of 9.99% and 8.8% respectively.

AWM Investment Company, Inc. has reported a 5.8% beneficial ownership stake in Aytu BioPharma, Inc. as of December 31, 2025.

Laurence W. Lytton and the Lytton-Kambara Foundation reported a combined beneficial ownership of 9.99% in AYTU BIOPHARMA, INC common stock.

Philotimo Fund and related entities report zero beneficial ownership in Aytu BioPharma, Inc. as of September 30, 2025, marking a complete divestment.

AWM Investment Company, Inc. has reported a 6.9% beneficial ownership stake in Aytu BioPharma, Inc., holding 619,874 shares of common stock.

Stonepine Capital Management and its affiliates disclosed a continued 9.9% beneficial ownership stake in Aytu BioPharma, Inc., comprising common stock and various warrants.